Zydus Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ZYDUS, and what generic alternatives to ZYDUS drugs are available?
ZYDUS has three hundred and sixty-eight approved drugs.
There is one US patent protecting ZYDUS drugs. There are twenty-six tentative approvals on ZYDUS drugs.
There are four patent family members on ZYDUS drugs in four countries and nine hundred and fifteen supplementary protection certificates in eighteen countries.
Summary for Zydus
| International Patents: | 4 |
| US Patents: | 1 |
| Tradenames: | 298 |
| Ingredients: | 289 |
| NDAs: | 368 |
| Patent Litigation for Zydus: | See patent lawsuits for Zydus |
Drugs and US Patents for Zydus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zydus Pharms | ARIPIPRAZOLE | aripiprazole | TABLET;ORAL | 090472-001 | Jan 7, 2019 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Zydus Pharms | LURASIDONE HYDROCHLORIDE | lurasidone hydrochloride | TABLET;ORAL | 208052-004 | Mar 19, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Zydus Pharms | TADALAFIL | tadalafil | TABLET;ORAL | 206693-003 | Mar 26, 2019 | AB1 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Zydus Lifesciences | VALACYCLOVIR HYDROCHLORIDE | valacyclovir hydrochloride | TABLET;ORAL | 079137-001 | Dec 29, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Zydus Pharms Usa | VENLAFAXINE HYDROCHLORIDE | venlafaxine hydrochloride | TABLET;ORAL | 077653-001 | Jun 13, 2008 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Zydus Hlthcare | DULOXETINE HYDROCHLORIDE | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 090739-003 | Jan 8, 2014 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Zydus Pharms | NIFEDIPINE | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 210184-003 | Jun 29, 2018 | AB1 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for ZYDUS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
International Patents for Zydus Drugs
Supplementary Protection Certificates for Zydus Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1084705 | CR 2014 00065 | Denmark | ⤷ Sign Up | PRODUCT NAME: LINAGLIPTIN; REG. NO/DATE: EU/1/11/707/001-011 20110830 |
| 0720599 | 300688 | Netherlands | ⤷ Sign Up | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ROSUVASTATINE; NATIONAL REGISTRATION NO/DATE: RVG114002-004 20140811; FIRST REGISTRATION: NO 13-9663 - 9665 20140724 |
| 2316456 | C201730057 | Spain | ⤷ Sign Up | PRODUCT NAME: NALTREXONA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, EN PARTICULAR CLORHIDRATO DE NALTREXONA, Y BUPROPION O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR CLORHIDRATO DE BUPROPION.; NATIONAL AUTHORISATION NUMBER: EU/1/14/988; DATE OF AUTHORISATION: 20150326; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/988; DATE OF FIRST AUTHORISATION IN EEA: 20150326 |
| 0253738 | 96C0009 | Belgium | ⤷ Sign Up | PRODUCT NAME: CONCENTRE A 85 % D'OMEGA POLYINSATURES; QUANTITE CORRESPONDANT A :; ESTERS ETHYLIQUES D'ACIDE EICOSAPENTAENOIQUE (EPA) ET D'ACIDE DOCOSAHEXAENOIQUE (DHA); ALPHA TOCOPHEROL; NAT. REGISTRATION NO/DATE: NL 20819 19951002; FIRST REGISTRATION: |
| 2487163 | 132017000002807 | Italy | ⤷ Sign Up | PRODUCT NAME: COBICISTAT O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE E ATAZANAVIR O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE, IN PARTICOLARE ATAZANAVIR SOLFATO(EVOTAZ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1025, 20150715 |
| 0206283 | SPC/GB97/085 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: LEVOFLOXACIN, OPTIONALLY IN THE FORM OF A HEMIHYDRATE; REGISTERED: UK 13402/0011 19970606; UK 13402/0012 19970606; UK 13402/0013 19970606 |
| 1429780 | 13C0012 | France | ⤷ Sign Up | PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
